CONTEXT: On the back of previous news stories about genetic biomarker testing in NSCLC, Neogenomics announces the launch of KRAS G12C testing to eligible advanced / late stage NSCLC cancer patients at no cost. This appears to be as a result of real-world biomarker testing showing gaps in testing rates compared to recommended guidelines. Interesting tactic to move the needle on this one.
IMPACT: Medium
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 8
1. “The sponsored testing program will leverage NeoGenomics’ experience in biomarker testing, with Amgen funding the total cost of the tests performed by NeoGenomics, regardless of patient’s insurance coverage or test results.”
2. “FT. MYERS, FL / ACCESSWIRE / April 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, is excited to launch an Amgen-sponsored testing program to support single-gene molecular testing for the biomarker KRAS G12C for eligible lung cancer patients at no cost to the patient.”
3. “As part of Amgen’s Biomarker AssistTM KRAS Single Gene Testing Program, Amgen will sponsor testing for the KRAS G12C biomarker for patients suffering from advanced or metastatic (stage IV) non-small cell lung cancer (NSCLC) through NeoGenomics.”
4. “Amgen’s Biomarker AssistTM program is designed to help more patients with advanced non-small cell lung cancer gain access to testing.”
5. “All patients with advanced or metastatic (stage IV) non-small cell lung cancer may be eligible to participate in the Biomarker AssistTM KRAS Single Gene Testing Program.”
Source URL: https://finance.yahoo.com/news/neogenomics-announces-launch-biomarker-assist-110000252.html